Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
SAN MATERO, Calif. and CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marc Besman Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance.
- SAN MATERO, Calif. and CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marc Besman Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance.
- He will also ensure that the Company upholds the highest levels of clinical quality compliance.
- “As we progress our clinical programs, regulatory strategy will be critical for Kronos Bio’s continued success,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
- I’m confident that Marc will make meaningful contributions to Kronos Bio as we plan for the future of KB-0742 and lanraplenib as well as our discovery programs.”
Dr. Besman joins Kronos Bio from Coherus BioSciences where he served as Senior Vice President of Regulatory Affairs.